Sanuwave Health, Inc. is a medical technology company focused on the development and commercialization of non‐invasive biological stimulation therapies for wound care and musculoskeletal indications. The company’s flagship product, dermaPACE®, employs patented extracorporeal shockwave technology designed to accelerate healing in chronic and acute wounds. Sanuwave combines proprietary acoustic wave delivery systems with specialized disposable applicators to treat diabetic foot ulcers, venous leg ulcers, pressure injuries, and other hard‐to‐heal wounds.
In addition to wound care, Sanuwave is advancing clinical research in the skeletal muscle reconditioning market. The company’s proprietary Pulse Activated Cellular Therapy (PACT™) platform is being investigated for applications in muscle regeneration, orthopedic rehabilitation, and soft tissue healing. By leveraging both high‐energy acoustic waveforms and focused shockwave delivery, Sanuwave aims to address unmet needs in tissue repair and functional recovery without the use of drugs or invasive procedures.
Founded in the mid-2000s, Sanuwave has evolved through multiple stages of product development, regulatory approvals, and commercial launch. The company’s dermaPACE system received 510(k) clearance from the U.S. Food and Drug Administration for adjunctive treatment of chronic, non-healing wounds. Beyond the U.S., Sanuwave has established distribution agreements in Europe, Latin America, and Asia-Pacific regions, working closely with hospitals, wound care centers, and large healthcare networks to deliver its therapy in both inpatient and outpatient settings.
Sanuwave’s leadership team brings together seasoned professionals in medical device development, regulatory affairs, and global commercialization. The executive group includes executives who have previously held senior roles at leading medtech companies and have overseen successful product launches and regulatory filings worldwide. Supported by a board of directors with deep expertise in healthcare innovation, Sanuwave continues to expand its clinical pipeline and pursue strategic partnerships to drive broader adoption of its non‐invasive therapeutic solutions.
AI Generated. May Contain Errors.
